LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
33 funds hold it · Insiders net selling
Net selling: insiders sold $1.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 2, 2026
Period ending
Sep 30, 2026
Earnings per share
-$0.11 expected
Estimates as of Nov 8, 2026
EPS expected
$1.33 to $1.71
Revenue expected
10 analysts
Last 30 days
Split both ways
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 2, 2026 | $0.23est. -$0.11 | +$0.34beat | $1.02BSEC filing | +32.0%from $776.1M |
| Jun 30, 2026Reported Aug 6, 2026 | $1.20est. $0.95 | +25.75%beat | $989.7MSEC filing | +19.9%from $825.4M |
| Mar 31, 2026Reported May 4, 2026 | $0.76est. $0.91 | -16.86%miss | $766.2MSEC filing | +2.8%from $745.1M |
| Dec 31, 2025Reported Feb 23, 2026 | $0.46est. $0.56 | -17.94%miss | $874.6MAlpha Vantage | +17.0%from $747.3M |
| Sep 30, 2025Reported Oct 27, 2025 | $0.12est. $0.34 | -64.71%miss | $776.1MSEC filing | +4.1%from $745.7M |
| Jun 30, 2025Reported Aug 4, 2025 | $1.44est. $1.03 | +39.81%beat | $825.4MSEC filing | +15.9%from $712.0M |
| Mar 31, 2025Reported May 1, 2025 | $1.13est. $0.95 | +18.95%beat | $745.1MSEC filing | +14.8%from $648.8M |
| Dec 31, 2024Reported Feb 19, 2025 | $0.92est. $0.74 | +24.56%beat | $747.3MAlpha Vantage | +15.6%from $646.2M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $874.6M | $766.2M | $989.7M | $1.02B |
| Cost of what it sold | $295.1M | $195.0M | $202.8M | $205.4M |
| Gross profit | $579.5M | $571.2M | $786.9M | $819.2M |
| What it spent | ||||
| Research and development | $192.4M | $178.8M | $207.0M | $180.5M |
| Sales and admin | $802.1M | $133.4M | $253.3M | $333.6M |
| Other operating costs | -$494.4M | $129.4M | $215.7M | $387.1M |
| Total operating expenses | $500.1M | $441.6M | $676.0M | $901.3M |
| What was left | ||||
| Operating profit | $79.4M | $129.6M | $110.9M | -$82.1M |
| Interest on debt | $2.8M | $15.0M | $63.3M | $55.6M |
| Profit before tax | -$27.2M | $141.2M | $61.4M | -$131.8M |
| Tax | $19.4M | $35.7M | $16.6M | -$8.9M |
| Net profit | -$46.6M | $105.5M | $44.8M | -$122.8M |
| EBITDA | -$3.9M | $172.6M | $222.3M | $54.3M |
This stock's price action is mixed.
Trend
Mixed
55 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is mixed
Weekly Recap: Q3 revenue up, 2026 guidance cut and analyst target cuts
Leans bearishNov 9Biopharma Co. Reports First Quarterly Revenue Above US$1 Billion as Acquisition Expands Portfolio
NeutralNov 6Four undervalued healthcare stocks with the highest year-over-year CapEx growth
Leans bullishNov 5H.C. Wainwright reiterates BioMarin stock rating at Neutral
NeutralNov 4Three talks by rare-disease drugmaker BioMarin will be available live online.
NeutralNov 4BioMarin to Participate in Upcoming Investor Conferences
NeutralNov 4H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
Leans bearishNov 4Biomarin Pharmaceutical (BMRN) Stock Price, Chart & Analysis
NeutralNov 436 macro signals shaping BMRN right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
